We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
-$39.5M
Cap. Flow %
-27.17%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Buys

1
CNC icon
Centene
CNC
+$6.93M
2
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.78M
3
UNH icon
UnitedHealth
UNH
+$3.65M
4
CVS icon
CVS Health
CVS
+$3.53M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M

Top Sells

1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

1 Healthcare 48.9%
2 Financials 13.82%
3 Technology 6.61%
4 Consumer Discretionary 5.8%
5 Materials 5.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
151
Moderna
MRNA
$24.5B
$118K 0.08%
+4,583
New +$128K
TNYA icon
152
Tenaya Therapeutics
TNYA
$177M
$117K 0.08%
+72,494
New +$73K
AYTU icon
153
AYTU BioPharma
AYTU
$23.1M
$117K 0.08%
+62,452
New +$144K
OLMA icon
154
CALL
Olema Pharmaceuticals
OLMA
$1B
$116K 0.08%
+209
New +$1.25K
MNKD icon
155
CALL
MannKind Corp
MNKD
$1.25B
$115K 0.08%
2,393
+1,196
+100% +$5.25K
MRNA icon
156
PUT
Moderna
MRNA
$24.5B
$108K 0.07%
230
-45,252
-99% -$1.26M
AVR
157
Anteris Technologies
AVR
$823M
$105K 0.07%
23,317
– –
C icon
158
CALL
Citigroup
C
$217B
$102K 0.07%
+151
New +$14.3K
VNET
159
VNET Group
VNET
$2.1B
$99.7K 0.07%
+9,651
New +$81.3K
AS icon
160
Amer Sports
AS
$21.2B
$99K 0.07%
+2,849
New +$107K
EQ icon
161
Equillium
EQ
$164M
$98.7K 0.07%
+68,991
New +$73K
ALEC icon
162
Alector
ALEC
$167M
$92.5K 0.06%
31,240
-29,856
-49% -$65.8K
JAZZ icon
163
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
$89.2K 0.06%
229
+114
+99% +$13.7K
SKYE icon
164
CALL
Skye Bioscience
SKYE
$22.8M
$80.8K 0.06%
+688
New +$2.6K
PRQR icon
165
ProQR Therapeutics
PRQR
$240M
$77.3K 0.05%
36,280
– –
PYXS icon
166
Pyxis Oncology
PYXS
$150M
$76.9K 0.05%
+34,632
New +$49.9K
CAPR icon
167
CALL
Capricor Therapeutics
CAPR
$1.13B
$72.6K 0.05%
+689
New +$5.07K
MBX
168
CALL
MBX Biosciences
MBX
$2.99B
$71.8K 0.05%
+230
New +$3.08K
KOD icon
169
CALL
Kodiak Sciences
KOD
$2.67B
$68.5K 0.05%
+64
New +$552
PTHS
170
Pelthos Therapeutics
PTHS
$93.8M
$67.3K 0.05%
+2,403
New +$58.3K
RARE icon
171
Ultragenyx Pharmaceutical
RARE
$2.88B
$62.6K 0.04%
2,082
-10,355
-83% -$311K
OVID icon
172
Ovid Therapeutics
OVID
$455M
$59.9K 0.04%
+46,040
New +$39.9K
RARE icon
173
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$59.5K 0.04%
347
-153
-31% -$4.59K
NEUP
174
Neuphoria Therapeutics
NEUP
$18.5M
$57.9K 0.04%
+4,908
New +$45.6K
CLYM
175
Climb Bio
CLYM
$727M
$56.7K 0.04%
28,221
-116,958
-81% -$217K
5 6
7
8 9

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners withdrew a net $39.5M in Q3 2025, closing 75 positions and reducing 59 holdings. Its most notable exit was Humana, an estimated $4.91M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Persistent Asset Partners opened a new position in Centene worth $8.19M.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.